Can pancreaticoduodenectomy be used to palliate selective metastatic malignancies? case report of malignant fibrous histiocytoma

Abstract

Pancreaticoduodenectomy is the accepted surgical treatment for resectable periampullarymalignancies.1 These tumors are generally adenocarcinomas of the pancreas, distal common bile duct, duodenum, and ampulla of Vater and are relatively resistant to other forms of treatment (i.e., chemotherapy, radiotherapy, or both), and a margin-negative (R0) resection is the only chance for cure.2 The first successful pancreaticoduodenectomy was reported by Kausch in Germany in 1912 and gained notoriety in the United States after the report by Whipple in 1935.3 Since its original description, the operation has undergone many modifications and technical refinements.4 Over the past two decades, numerous large case series from high-volume centers have reported dramatic improvements in the operative morbidity andmortality rates associated with this operation.1,5–8 In this report, we present a unique case of malignant metastatic fibrous histiocytoma treated by pancreaticoduodenectomy and use it as a paradigm to justify extending the indications for this operation, in select settings, for surgical palliation of selective metastatic malignancies.

DOI: 10.1016/j.gassur.2005.04.014

2 Figures and Tables

Cite this paper

@article{BS2005CanPB, title={Can pancreaticoduodenectomy be used to palliate selective metastatic malignancies? case report of malignant fibrous histiocytoma}, author={Mindy M. Ho B.S. and Thomas J. Howard and Keith D. Lillemoe}, journal={Journal of Gastrointestinal Surgery}, year={2005}, volume={9}, pages={934-937} }